Myocardial Infarction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: May 31, 2022 Report Code: GDGMDHC22161IDB-ST

Select Item

The Myocardial infarction pipeline market research report provides a comprehensive overview on the therapeutics under development for Myocardial infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial infarction and features dormant and discontinued projects.

Key Targets in the Myocardial infarction Pipeline Drugs Market

In the Myocardial Infarction pipeline drugs market the key targets are P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Free Radical, Integrin Alpha 2b, Actin, Integrin Beta 3, Interleukin 1 Beta, Mitogen Activated Protein Kinase Kinase Kinase 5, Plasminogen, Sodium/Glucose Cotransporter 2, 72 kDa Type IV Collagenase, and Adenosine Receptor A2b.

Myocardial Infarction Drugs Market, by Targets

Myocardial Infarction Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Myocardial Infarction Pipeline Drugs Market

P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y Antagonist has the highest number of pipeline products followed by, Free Radical Scavenger, Integrin Alpha 2b Antagonist, Actin Inhibitor, Integrin Beta 3 Antagonist, Interleukin 1 Beta Inhibitor, Mitogen Activated Protein Kinase Kinase Kinase 5 Inhibitor, Plasminogen, Sodium/Glucose Cotransporter 2 Inhibitor, 72 kDa Type IV Collagenase Inhibitor, and Adenosine Receptor A2b Antagonist.

Myocardial Infarction Pipeline Drugs Market, by MoA

Myocardial Infarction Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Myocardial Infarction Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Myocardial Infarction pipeline drugs market are Intravenous, Oral, Subcutaneous, Intracoronary, Parenteral, Intracardiac, Intramuscular, Intravenous Bolus, Inhalational, Intraarticular, Intrathecal, and Ophthalmic. Intravenous has the maximum number of pipeline products.

Myocardial Infarction Pipeline Drugs Market Analysis, by RoA

Myocardial Infarction Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Myocardial Infarction Pipeline Drugs Market

The key molecule types in the Myocardial Infarction pipeline drugs market are Small Molecule, Cell Therapy, Recombinant Protein, Monoclonal Antibody, Fusion Protein, Recombinant Enzyme, Biologic, Oligonucleotide, Recombinant Peptide, and Synthetic Peptide.

Myocardial Infarction Pipeline Drugs Market, by Molecule Type

Myocardial Infarction Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Myocardial Infarction Pipeline Drugs Market

The major companies in the Myocardial Infarction pipeline drugs market are AstraZeneca Plc, Mesoblast Ltd, APT Therapeutics Inc, Cardior Pharmaceuticals GmbH, CeleCor Therapeutics Inc, Celixir Ltd, Curacle Co Ltd, Ever Supreme Bio Technology Co Ltd, MIFCOR Inc, and NuvOx Pharma LLC.

Myocardial Infarction Pipeline Drugs Market, by Major Companies

Myocardial Infarction Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Myocardial Infarction Pipeline Drugs Market Overview

Key Targets P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Free Radical, Integrin Alpha 2b, Actin, Integrin Beta 3, Interleukin 1 Beta, Mitogen Activated Protein Kinase Kinase Kinase 5, Plasminogen, Sodium/Glucose Cotransporter 2, 72 kDa Type IV Collagenase, and Adenosine Receptor A2b
Key Mechanisms of action P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y Antagonist, Free Radical Scavenger, Integrin Alpha 2b Antagonist, Actin Inhibitor, Integrin Beta 3 Antagonist, Interleukin 1 Beta Inhibitor, Mitogen Activated Protein Kinase Kinase Kinase 5 Inhibitor, Plasminogen, Sodium/Glucose Cotransporter 2 Inhibitor, 72 kDa Type IV Collagenase Inhibitor, and Adenosine Receptor A2b Antagonist
Key Routes of Administration Intravenous, Oral, Subcutaneous, Intracoronary, Parenteral, Intracardiac, Intramuscular, Intravenous Bolus, Inhalational, Intraarticular, Intrathecal, and Ophthalmic
Key Molecule Types Small Molecule, Cell Therapy, Recombinant Protein, Monoclonal Antibody, Fusion Protein, Recombinant Enzyme, Biologic, Oligonucleotide, Recombinant Peptide, and Synthetic Peptide
Major Companies AstraZeneca Plc, Mesoblast Ltd, APT Therapeutics Inc, Cardior Pharmaceuticals GmbH, CeleCor Therapeutics Inc, Celixir Ltd, Curacle Co Ltd, Ever Supreme Bio Technology Co Ltd, MIFCOR Inc, and NuvOx Pharma LLC

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction
  • The pipeline guide reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Infarction therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Infarction therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Myocardial Infarction

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Abcentra LLC
Acticor Biotech SAS
Actinogen Medical Ltd
Angion Biomedica Corp
Animatus Biosciences LLC
Ankasa Regenerative Therapeutics Inc
Aposcience AG
Aprogen Inc
APT Therapeutics Inc
AptaTargets SL
AstraZeneca Plc
Athera Biotechnologies AB
Athersys Inc
Axolo Pharma Inc
Bayer AG
Beijing Northland Biotech Co Ltd
Bharat Biotech Ltd
BlueRock Therapeutics LLC
Boehringer Ingelheim International GmbH
Brexogen Inc
Cardior Pharmaceuticals GmbH
CeleCor Therapeutics Inc
Celixir Ltd
Cell Tech Pharmed Co
CellProthera SAS
CFM Pharma Holding BV
Chengdu Shibeikang Biomedical Technology Co Ltd
Curacle Co Ltd
Cynata Therapeutics Ltd
Diapin Therapeutics LLC
Diffusion Pharmaceuticals Inc
Domainex Ltd
Eight Plus One Pharmaceutical Co Ltd
EndoProtech Inc
Ever Supreme Bio Technology Co Ltd
Evotec SE
EyeGene Inc
Faraday Pharmaceuticals Inc
Forcefield Therapeutics Ltd
General Regeneratives Shanghai Ltd
Generium
GNT Pharma Co Ltd
Hemostemix Inc
Heqet Therapeutics Srl
Hetero Drugs Ltd
Honya Medical Inc
HUYA Bioscience International LLC
Idorsia Pharmaceutical Ltd
iHeart Japan Corp
InCarda Therapeutics Inc
Innolife Co Ltd
Inotrem SA
IPCA Laboratories Ltd
IPS Heart Inc
Kine Sciences
LTT Bio-Pharma Co Ltd
MandalMed Inc
Marizyme Inc
Merck & Co Inc
Mesoblast Ltd
MIFCOR Inc
MimeTech Srl
Mirae Cell Bio Co Ltd
New World Laboratories Inc
Nexel Co Ltd
Novartis AG
NuvOx Pharma LLC
OtiTopic Inc
Oxstem Ltd
Pharmahungary Group
Primary Peptides Inc
Qurgen Inc
R-Pharm
Reata Pharmaceuticals Inc
Recardio Inc
RegeneRx Biopharmaceuticals Inc
Remedium Bio Inc
ResoTher Pharma ApS
Ribomic Inc
RION Health Inc
Rubicon Biotechnology Inc
Sentan Pharma Inc
Serca Pharmaceuticals AS
Serpin Pharma LLC
Silver Creek Pharmaceuticals Inc
SmartPharm Therapeutics Inc
Sorrento Therapeutics Inc
T&R Biofab Co Ltd
Takeda Pharmaceutical Co Ltd
Thrombolytic Science International LLC
Translational Sciences Inc
TreeFrog Therapeutics SAS
Vaxil Bio Therapeutics Ltd
Viridian Therapeutics Inc
XBiotech Inc
Yichang Humanwell Pharmaceutical Co Ltd
Yuyu Pharma Inc
Zensun (Shanghai) Sci & Tech Co Ltd
Zydus Lifesciences Ltd
Zylem Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myocardial Infarction – Overview

Myocardial Infarction – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myocardial Infarction – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myocardial Infarction – Companies Involved in Therapeutics Development

Myocardial Infarction – Drug Profiles

Myocardial Infarction – Dormant Projects

Myocardial Infarction – Discontinued Products

Myocardial Infarction – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Myocardial Infarction, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Products under Development by Universities/Institutes, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Myocardial Infarction – Dormant Projects, 2022

Myocardial Infarction – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Myocardial Infarction, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Myocardial Infarction pipeline drugs market?

    In the Myocardial Infarction pipeline drugs market the key targets are P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Free Radical, Integrin Alpha 2b, Actin, Integrin Beta 3, Interleukin 1 Beta, Mitogen Activated Protein Kinase Kinase Kinase 5, Plasminogen, Sodium/Glucose Cotransporter 2, 72 kDa Type IV Collagenase, and Adenosine Receptor A2b.

  • What are the key mechanisms of action in the Myocardial Infarction pipeline drugs market?

    In the Myocardial Infarction pipeline drugs market the key mechanisms of action are P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y Antagonist, Free Radical Scavenger, Integrin Alpha 2b Antagonist, Actin Inhibitor, Integrin Beta 3 Antagonist, Interleukin 1 Beta Inhibitor, Mitogen Activated Protein Kinase Kinase Kinase 5 Inhibitor, Plasminogen, Sodium/Glucose Cotransporter 2 Inhibitor, 72 kDa Type IV Collagenase Inhibitor, and Adenosine Receptor A2b Antagonist.

  • What are the key routes of administration in the Myocardial Infarction pipeline drugs market?

    The key routes of administration in the Myocardial Infarction pipeline drugs market are Intravenous, Oral, Subcutaneous, Intracoronary, Parenteral, Intracardiac, Intramuscular, Intravenous Bolus, Inhalational, Intraarticular, Intrathecal, and Ophthalmic.

  • What are the key molecule types in the Myocardial Infarction pipeline drugs market?

    The key molecule types in the Myocardial Infarction pipeline drugs market are Small Molecule, Cell Therapy, Recombinant Protein, Monoclonal Antibody, Fusion Protein, Recombinant Enzyme, Biologic, Oligonucleotide, Recombinant Peptide, and Synthetic Peptide.

  • What are the major companies in the Myocardial Infarction pipeline drugs market?

    In the Myocardial Infarction pipeline drugs market the major companies are AstraZeneca Plc, Mesoblast Ltd, APT Therapeutics Inc, Cardior Pharmaceuticals GmbH, CeleCor Therapeutics Inc, Celixir Ltd, Curacle Co Ltd, Ever Supreme Bio Technology Co Ltd, MIFCOR Inc, and NuvOx Pharma LLC.

Myocardial Infarction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Cardiovascular reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Myocardial Infarction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Myocardial Infarction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more